Genmab — April 2017

[Sibelius]

I also agree that it is unlikely that Genmab remain independent for ten years more - or five for that matter.

[Sibelius]

However, before getting lost in P/E calculations etc., we should also consider what the strategy of the company is, and how this will change the operations and earings multiples.

[Sibelius]

Genmab will - if strategy becomes action and reality - become a completely different animal.

[Sibelius]

This will include a lot more investment - and risk - in new R&D. Also, taking greater responsibility for approvals, market launch and global sales of new products will lead to much higher leverage and roll-out risks.

[Sibelius]

It is quite difficult to factor all this in to the current stock price and current analyst targets. This is why targets are quite modest, as most are concerned with the next 4-6 years in their forecasts.

[Sibelius]

As Keynes said: In the long run we will all be dead anyways:-)

[transalp]

Hahaahaha Sibelius.. : )

[GlobalMacro 0]

@Sibelius, Good builds, agree with most of your views. Regarding P/E, Genmab's strategy - different animal, I also believe that will happen. In my analysis I was only accounting for Dara in MM, not outside MM, Arzerra in MS and other molecules etc. Therefore, yes Genmab will take much more risk in the future, I believe against that will also be much more earnings, Based on certain data and other sources I believe Dara in solid tumors will be a big succes and therefore

[GlobalMacro 0]

drive a lot of extra earnings fast.

[GlobalMacro 0]

And remember, we don't have to wait years and years for Dara in solid tumors. When the data is as good as JvdW believes, phase 2 studies can be approved and you don't have to wait for the big phase 3 studies

[hda]

Forventeligt Q1 fra J&J i eftermiddag. Er det ikke sådan det er?

[GeorgeBest]

JNJ kvartalsregnskab kommer 12:45.

[sowise]

Jo 0830 AM - http://www.investor.jnj.com/events.cfm

[GeorgeBest]

@sowise - det er webcast der starter 14:30.

[E_L]

coïncidence?? : Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
https://www.novartis.com/news/media-releases/novartis-car-t-cell-therapy-ctl019-receives-fda-breakthrough-therapy-designation

[gentogen]

Er der nogen særlig grund til at godkendelsen i Canada ikke bliver til en Genmab nyhed. den er vel mindst lige så vigtig som den seneste meget omtalte....

[Sukkeralf]

E L coincidence ??

[E_L]

I was thinking this would have been competition for the Phase II study Janssen just stopped? Am I correct?

[Sukkeralf]

I don´t think thats how it works

[E_L]

Maybe I search too far But JNJ has a lot of insight in these markets; if you know a competitor is more successful with a better product, it is wise to pull the plug
on your own trial.